Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DUX4 (Double Homeobox 4) is a transcription factor crucial for early embryonic development. Its expression is normally tightly regulated but becomes aberrantly activated in diseases like facioscapulohumeral muscular dystrophy (FSHD), leading to muscle degeneration through apoptosis and impaired myogenesis. Therapeutic strategies focus on silencing DUX4 mRNA.
Antisense oligonucleotide-mediated silencing of DUX4 mRNA
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Double Homeobox Protein 4 (DUX4).